Rosetta, Prometheus Close Deal for miRNA Dx Market Rights

A separate deal under which Prometheus agreed to acquire 2 million shares of Rosetta at $4 per share has also been completed.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.